Phio Pharmaceuticals joins Renmark virtual non-deal roadshow

PHIO•2026-10-19

Phio Pharmaceuticals will participate in Renmark Financial Communications’ virtual non-deal roadshow on October 20, 2026, at noon EDT, with CEO Robert Bitterman presenting its INTASYL siRNA platform and lead candidate PH-762.

1. Roadshow presentation

CEO Robert Bitterman will present Phio Pharmaceuticals’ INTASYL siRNA platform, including lead candidate PH-762 for cutaneous carcinomas, followed by a live Q&A.

Phio Pharmaceuticals joins Renmark virtual non-deal roadshow

1. Roadshow presentation

Related News

Microsoft reportedly pulls out of UK Nscale data centre deal over power delay

Amex trading halted; last price 2.920000

VinFast's overseas push lifts quarterly revenue as restructuring gains trim net loss

ConnectM targets data center power infrastructure expansion

UBS raises Quest Diagnostics target price to $250 from $245